

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



EVEREST MEDICINES

云 頂 新 耀

Everest Medicines Limited

雲 頂 新 耀 有 限 公 司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1952)

INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2022

The board of directors (the “**Board**”) of Everest Medicines Limited (the “**Company**”) announces the unaudited interim results of the Company and its subsidiaries for the six months ended 30 June 2022. This announcement, containing the full text of the 2022 interim report of the Company, complies with the relevant requirements of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) in relation to information accompanying preliminary announcements of interim results.

These interim results have been reviewed by the Company’s audit committee and the Company’s auditors, PricewaterhouseCoopers.

Both the Chinese and English versions of this results announcement are available on the websites of the Company (www.everestmedicines.com) and the Stock Exchange (www.hkexnews.hk). The 2022 interim report of the Company will be published on the websites of the Stock Exchange and the Company and printed versions of the same will be despatched to shareholders of the Company who have chosen to receive printed versions of the Company’s corporate communications by the end of September 2022.

By Order of the Board
Everest Medicines Limited
Wei Fu
Chairman and Executive Director

Hong Kong, 24 August 2022

As at the date of this announcement, the Board comprises Mr. Wei Fu as Chairman and Executive Director, Dr. Kerry Levan Blanchard, Mr. Ian Ying Woo and Mr. Xiaofan Zhang as Executive Directors, Mr. Yubo Gong and Ms. Lan Kang as Non-executive Directors, and Mr. Bo Tan, Mr. Yifan Li and Mr. Shidong Jiang as Independent Non-executive Directors.